Cancer clinical trials aim to improve the outlook for people with cancer. Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases. Together, these approaches offer great promise in the fight against cancer.
Although founded over 100 years ago, immunotherapy is still very much in its infancy. As of today, there are only a handful of immunotherapy drugs that have been approved by the FDA for use against specific types of cancer, but there are over 800 ongoing immunotherapy clinical trials in various phases for different cancers.
I’m excited to share with you news of a clinical trial that is providing innovative treatment options using immunotherapy for patients fighting advanced-stage cancers. This trial is currently enrolling patients with metastatic sarcoma*, pancreatic cancer, lung cancer, triple negative breast cancer or other different gynecological cancers. (*My husband had metastatic sarcoma so any time I hear about potential progress targeted at sarcoma, I get seriously excited.)
This phase Ib/ II trial known as “PembroPlus” is open for enrollment at Cancer Treatment Centers of America (CTCA) in Arizona. There are several arms to this trial meaning that different groups of patients will receive different chemotherapy drugs in combination with the FDA-approved for melanoma immunotherapy drug called Pembrolizumab.
As with all CTCA patients, they will cover the cost of travel to their facility for eligible patients and in some cases, the caregiver as well. For more information, visit clinicaltrials.gov or contact Cancer Treatment Centers of America directly at 888-841-9129.